Pesquisar
Bicycle Therapeutics PLC
BCYCAdicionar à lista de desejos
3.735USD
+0.105+2.89%
Horário de mercado 09/22, 12:20（ET）
188.16MValor de mercado
PerdaP/L TTM
Sobre o {index_name} Bicycle Therapeutics PLC Empresa
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics PLC Perfil
Código da empresaBCYC
Nome da EmpresaBicycle Therapeutics PLC
Data de listagemMay 23, 2019
CEOLee (Kevin)
Número de funcionários305
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 23
EndereçoBlocks A & B, Portway Building
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCB21 6GS
Telefone11441223261503
Sitehttps://www.bicycletherapeutics.com/
Código da empresaBCYC
Data de listagemMay 23, 2019
CEOLee (Kevin)
Executivos da empresa Bicycle Therapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
758.00
-300.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Perguntas frequentes
Quem são os cinco principais acionistas de Bicycle Therapeutics PLC?
Os cinco principais acionistas de Bicycle Therapeutics PLC são: Dr. Kevin Lee, Ph.D.
Quantas instituições possuem ações da Bicycle Therapeutics PLC (BCYC)?
Em 2026Q1, 250 instituições possuíam ações da Bicycle Therapeutics PLC, com valor de mercado aproximado de 33.87M, representando 67.23% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -23140757.00.